title: [Rifampicin in the therapy of gonorrheal urethritis in men].
abstract: The therapeutic efficiency of benemycin (rifampicin of Polish production), a semisynthetic antibiotic was studied in 96 male cases with gonorrhea urethritis. The antibiotic was used in a dose of 300 mg every 6 hours (2.1--3gm for the treatment course depending on the desease severity). Observation of the patients for 1--2 months showed etiological recovery in 91 (94.8 per cent) out of 96 patients. Postgonorrhea inflammatory processes were observed in 8.7 per cent of the cases. For studying late results of the treatmant 62 patients were observed for 3 to 12 months. Gonococci were isolated from none of the patients. No side reactions were found in the patients treated with rifampicin.
mesh_terms: D000208:Acute Disease; D000328:Adult; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014526:Urethritis / Q000188:drug therapy*
chemical_list: D012293:Rifampin
vernacular_title: Rifampitsin v terapii gonoreĭnykh uretritov u muzhchin